Table 2.
Exposure Duration | 4 Days | 14 Days | ||||||
---|---|---|---|---|---|---|---|---|
PFOA (w/v) | 0% | 0.5% | 1% | 2% | 0% | 0.5% | 1% | 2% |
Cellularity (× 106) | 4.50 ± 0.85 | 5.11 ± 0.66 | 4.94 ± 0.53 | 9.02 ± 1.31* | 4.69 ± 0.65 | 3.73 ± 0.29 | 2.34 ± 0.23* | 2.86 ± 0.42** |
CD4+ (× 106) | 2.34 ± 0.43 | 2.70 ± 0.35 | 2.60 ± 0.26 | 4.70 ± 0.68* | 2.57 ± 0.35 | 2.06 ± 0.19 | 1.09 ± 0.13** | 1.20 ± 0.19** |
CD4+ (%) | 52.12 ± 0.93 | 52.94 ± 0.50 | 52.96 ± 0.65 | 52.30 ± 1.06 | 54.82 ± 0.96 | 55.10 ± 0.78 | 46.18 ± 1.55* | 41.90 ± 1.73** |
CD8+ (× 106) | 1.09 ± 0.16 | 1.27 ± 0.16 | 1.18 ± 0.13 | 2.19 ± 0.31* | 1.11 ± 0.14 | 1.01 ± 0.61 | 0.73 ± 0.07 | 0.87 ± 0.01 |
CD8+ (%) | 24.90 ± 1.07 | 24.98 ± 0.28 | 23.84 ± 0.53 | 24.36 ± 0.23 | 23.78 ± 0.63 | 27.36 ± 0.91 | 31.53 ± 1.39** | 30.76 ± 0.30** |
B-cells (× 106) | 0.72 ± 0.17 | 0.82 ± 0.11 | 0.85 ± 0.10 | 1.44 ± 0.23* | 0.87 ± 0.14 | 0.53 ± 0.04 | 0.39 ± 0.01* | 0.57 ± 0.10 |
B-cells (%) | 15.42 ± 1.23 | 16.00 ± 0.78 | 17.18 ± 0.85 | 15.92 ± 0.96 | 18.42 ± 1.17 | 14.32 ± 0.58* | 17.28 ± 1.41 | 19.64 ± 1.17 |
Dendritic Cells (× 104) | 3.02 ± 0.82 | 3.43 ± 0.44 | 3.39 ± 0.41 | 9.24 ± 0.13** | 2.36 ± 0.27 | 2.04 ± 0.19 | 1.63 ± 0.29 | 2.14 ± 0.23 |
Dendritic Cells (%) | 0.63 ± 0.08 | 0.67 ± 0.04 | 0.69 ± 0.04 | 1.03 ± 0.08** | 0.51 ± 0.03 | 0.55 ± 0.05 | 0.68 ± 0.06 | 0.77 ± 0.07** |
Monocytes (× 105) | 2.25 ± 0.44 | 1.82 ± 0.18 | 1.66 ± 0.19 | 4.06 ± 0.71* | 1.78 ± 0.28 | 1.36 ± 0.15 | 1.03 ± 0.16 | 1.41 ± 0.27 |
Monocytes (%) | 5.20 ± 0.91 | 3.68 ± 0.29 | 3.35 ± 0.08* | 4.43 ± 0.29 | 3.80 ± 0.38 | 3.71 ± 0.46 | 4.34 ± 0.47 | 4.87 ± 0.54** |
Lymph node immune phenotyping following 4 and 14 days of PFOA exposure. Numbers represent mean (± SE) of 5 mice per group. Levels of statistical significance are denoted (**p < 0.01 and * p < 0.05) as compared to acetone vehicle (0%).